# Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab

> **NCT03798691** · PHASE4 · COMPLETED · sponsor: **University of Wisconsin, Madison** · enrollment: 33 (actual)

## Conditions studied

- Inflammatory Bowel Diseases
- Crohn Disease
- Ulcerative Colitis
- Herpes Zoster

## Interventions

- **BIOLOGICAL:** Shingrix

## Key facts

- **NCT ID:** NCT03798691
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-28
- **Primary completion:** 2023-10-12
- **Final completion:** 2024-09-10
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2025-04-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03798691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03798691, "Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03798691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*